CorMedix Inc.

Total Valuation

CorMedix Inc. carries a market capitalization of 583.41M, placing it among publicly traded companies globally. Its enterprise value stands at 498.14M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

CorMedix Inc. currently has 77.67M shares outstanding.

Valuation Ratios

CorMedix Inc. trades at a trailing price-to-earnings ratio of 3.28. The price-to-sales ratio is 1.34, and the price-to-book ratio stands at 1.32.

Enterprise Valuation

On an enterprise value basis, CorMedix Inc. trades at an EV/EBITDA multiple of 1.97 and an EV/FCF ratio of 1.92. The EV/Sales ratio of 1.08 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 2.30 provides insight into valuation relative to core operating earnings.

Financial Position

CorMedix Inc. maintains a current ratio of 2.56, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 31.50, indicating elevated leverage, while an interest coverage ratio of 91.25 demonstrates strong ability to service its debt obligations.

Financial Efficiency

CorMedix Inc. posts a return on equity of 54.93 and a return on invested capital of 47.52.

Taxes

Over the trailing twelve months, CorMedix Inc. has paid 16.23M in income taxes, reflecting an effective tax rate of 7.98.

Stock Price Statistics

CorMedix Inc.'s stock has declined approximately -38.44572% over the past 52 weeks. The 50-day moving average sits at 7.83, while the 200-day moving average is 7.74.

Income Statement

Over the trailing twelve months, CorMedix Inc. generated 459.62M in revenue and converted that into 187.17M in net income, yielding earnings per share of 2.05. EBITDA reached 252.35M, while operating income came in at 217.04M.

Balance Sheet

CorMedix Inc. holds 256.69M in cash and equivalents against 145.15M in total debt, resulting in a net debt position of -111.54M. Total book value stands at 460.83M, with working capital of 293.16M providing operational flexibility.

Cash Flow

CorMedix Inc. produced 253.94M in operating cash flow over the past twelve months. After subtracting -3.52M in capital expenditures, free cash flow totaled 250.42M - equivalent to 3.20 per share.

Margins

CorMedix Inc. operates with a gross margin of 82.68, reflecting its pricing power and cost economics. The operating margin of 47.22 and net profit margin of 40.72 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

CorMedix Inc.'s most recent stock split took place on March 26, 2019 with a 5:1 split ratio.

Scores

CorMedix Inc. posts an Altman Z-Score of 3.48, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.